S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
NASDAQ:ATXS

Astria Therapeutics (ATXS) Stock Price, News & Analysis

$13.90
+0.30 (+2.21%)
(As of 02:27 PM ET)
Today's Range
$13.38
$14.79
50-Day Range
$7.11
$16.69
52-Week Range
$4.26
$16.90
Volume
443,624 shs
Average Volume
1.00 million shs
Market Capitalization
$763.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.75

Astria Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
56.3% Upside
$21.75 Price Target
Short Interest
Healthy
4.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.61mentions of Astria Therapeutics in the last 14 days
Based on 21 Articles This Week
Insider Trading
Acquiring Shares
$30 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.72) to ($1.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.34 out of 5 stars

Medical Sector

445th out of 938 stocks

Pharmaceutical Preparations Industry

210th out of 433 stocks

ATXS stock logo

About Astria Therapeutics Stock (NASDAQ:ATXS)

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

ATXS Stock Price History

ATXS Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
ATXS Apr 2024 2.500 put
ATXS Oct 2024 22.500 call
ATXS Mar 2024 22.500 call
ATXS Mar 2024 12.500 call
See More Headlines
Receive ATXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/04/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ATXS
Employees
59
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$21.75
High Stock Price Target
$27.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+56.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-72,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.33 per share

Miscellaneous

Free Float
53,036,000
Market Cap
$764.21 million
Optionable
Optionable
Beta
0.72

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

ATXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Astria Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Astria Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATXS shares.
View ATXS analyst ratings
or view top-rated stocks.

What is Astria Therapeutics' stock price target for 2024?

4 Wall Street analysts have issued 1-year target prices for Astria Therapeutics' shares. Their ATXS share price targets range from $17.00 to $27.00. On average, they anticipate the company's share price to reach $21.75 in the next year. This suggests a possible upside of 56.3% from the stock's current price.
View analysts price targets for ATXS
or view top-rated stocks among Wall Street analysts.

How have ATXS shares performed in 2024?

Astria Therapeutics' stock was trading at $7.68 at the beginning of 2024. Since then, ATXS stock has increased by 81.3% and is now trading at $13.92.
View the best growth stocks for 2024 here
.

Are investors shorting Astria Therapeutics?

Astria Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 2,010,000 shares, an increase of 18.2% from the February 29th total of 1,700,000 shares. Based on an average daily trading volume, of 1,040,000 shares, the short-interest ratio is currently 1.9 days. Approximately 4.5% of the company's shares are short sold.
View Astria Therapeutics' Short Interest
.

When is Astria Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ATXS earnings forecast
.

How were Astria Therapeutics' earnings last quarter?

Astria Therapeutics, Inc. (NASDAQ:ATXS) issued its earnings results on Monday, March, 4th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by $0.08.

When did Astria Therapeutics' stock split?

Astria Therapeutics's stock reverse split on the morning of Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Who are Astria Therapeutics' major shareholders?

Astria Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (9.03%), Vivo Capital LLC (5.60%), Vanguard Group Inc. (4.64%), Vanguard Group Inc. (3.74%), Armistice Capital LLC (3.56%) and Affinity Asset Advisors LLC (3.31%). Insiders that own company stock include Andrew Komjathy, Christopher Morabito and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Astria Therapeutics?

Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATXS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners